Bastarrachea RA, Laviada-Molina H, Vázquez-Chávez C

Idioma: Español
Referencias bibliográficas: 36
Paginas: 90-96
Archivo PDF: 87.04 Kb.

RESUMEN

En el último reporte del Comité de Expertos sobre el Diagnóstico y la Clasificación de la Diabetes Mellitus en Estados Unidos de América de noviembre del 2003, se recomienda la disminución de los puntos de corte para la glucemia de ayuno de menor o igual a 110 mg/dL, a menor o igual a 100 mg/dL. Por lo anterior, los valores “normales” de glucemia en ayunas deberán ser considerados de ahora en adelante menores a 100 mg/dL. Se establece oficialmente el diagnóstico clínico de pre-diabetes en ese país para sujetos con glucemia de ayuno de 100 a 125 mg/dL y 2 horas postcarga oral de 75 g de glucosa en niveles de 140 a 199 mg/gL. Estas nuevas recomendaciones seguramente tendrán fuertes implicaciones sobre los aspectos epidemiológicos, preventivos, de detección y tratamiento de la diabetes y del síndrome metabólico en el país, si México decide adoptarlas

REFERENCIAS (EN ESTE ARTÍCULO)

1. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20(7): 1183-1197.

2. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes 1979; 28(12): 1039-1057.

3. World Health Organization. Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727).

4. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Org., 1999.

5. DECODE Study Group on Behalf of the European Diabetes Epidemiology Study Group: Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ 1998; 317: 371-375.

6. Rathmann W, Giani G, Mielck A. Cardiovascular risk factors in newly diagnosed abnormal glucose tolerance: comparison of 1997 ADA and 1985 WHO criteria (Letter). Diabetologia 1999; 42: 1268-1269.

7. The DECODE Study Group, the European Diabetes Epidemiology Group: Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-404.

8. Little RR. Glycated hemoglobin standardization: National Glycohemoglobin Standardization Program (NGSP) Perspective (Review). Clin Chem Lab Med. In Press.

9. Rohlfing CL, Little RR, Wiedmeyer H, England JD, Madsen R, Harris MI, Flegal KM, Eberhardt MS, Goldstein DE. Use of GHb (HbA1c) in screening for undiagnosed diabetes in the US population. Diabetes Care 2000; 23: 187-191.

10. Molitch ME, Fujimoto W, Hamman RF, Knowler WC. Diabetes Prevention Program Research Group. The diabetes prevention program and its global implications. J Am Soc Nephrol 2003; 14(7 Suppl 2): S103-107.

11. Chiasson JL, Josse Rg, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002; 359: 2072-2077.

12. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP. Preservation of pancreatic b-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796-2803.

13. Shaw JE, Zimmet PZ, Hodge AM, de Courten M, Dowse GK, Chitson P, Tuomilehto J, Alberti KGMM. Impaired fasting glucose: how low should it go? Diabetes Care 2000; 23: 34-39.

14. The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group: Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003; 26: 688-696.

15. Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, Knowler WC. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000; 23: 1108-1112.

16. Unwin N, Shaw J, Zimmet P, Alberti KGMM. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002; 19: 708-723.

17. Bortheiry AL, Malerbi DA, Franco LJ. The ROC curve in the evaluation of fasting capillary blood glucose as a screening test for diabetes and IGT. Diabetes Care 2002; 17: 1269-1272.

18. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26(11): 3160-7.

19. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004; 27 Suppl 1: S11-S14.

20. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27 Suppl 1: S5-S10.

21. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27 Suppl 1: S15-S35.

22. Shrot RJ, Sahebzamani FM, Brownlee Jr HJ. Case Study: Screening and Treatment of Pre-Diabetes in Primary Care. Clin Diabetes 2004; 22(2): 98-100.

23. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. National Heart, Lung, and Blood Institute; American Heart Association. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004; 24(2): e13-e18.

24. Davidson MB, Landsman PB, Alexander CM. Lowering the Criterion for Impaired Fasting Glucose Will Not Provide Clinical Benefit. Diabetes Care 2003; 26(12): 3329-3330.

25. Schriger DL, Lorber B. Lowering the Cut Point for Impaired Fasting Glucose: Where is the evidence? Where is the logic? Diabetes Care 2004; 27(2): 592–595.

26. Davidson MB, Schriger DL, Peters AL, Lorber B. Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA 1999; 281(13): 1203-1210.

27. Meigs JB, Nathan DM, D’Agostino RB Sr, Wilson PW. Framingham Offspring Study. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002; 25(10): 1845-1850.

28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-2497.

29. Genuth S. Lowering the criterion for impaired fasting glucose is in order. Diabetes Care 2003; 26(12): 3331-3332.

30. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6): 393-403.

31. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344(18): 1343-1350.

32. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289(1): 76-79.

33. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22(2): 233-240.

34. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA, Wilson PW. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9(3): 237-252.

35. Engelgau MM. Diabetes Diagnostic Criteria and Impaired Glycemic States: Evolving Evidence Base Clin. Diabetes 2004; 22(2): 69-70.

36. Bastarrachea RA, Cole SA, Comuzzie AG. Genómica de la regulación del peso corporal: descifrando los mecanismos moleculares que predisponen a la obesidad. Med Clin (Barc) 2004. En prensa.